Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2025-02-27 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Bokslutskommuniké Januari - December 2024' (Year-end Report) for Vicore Pharma Holding AB. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary for the full fiscal year 2024 and the fourth quarter. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full annual report (10-K) but provides full financial disclosure. FY 2024
2025-02-27 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Year-end report January - December 2024' for Vicore Pharma Holding AB. It contains comprehensive financial statements, including income statements, balance sheets, and detailed management commentary on financial performance for the full fiscal year. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR) as it covers a specific period (year-end) and provides detailed financial analysis. FY 2024
2025-02-27 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a 'flaggningsmeddelande' (flagging notification). It details a change in shareholding by The Capital Group Companies, Inc. in Vicore Pharma Holding AB, crossing the 5% threshold. This is a standard major shareholding notification.
2024-11-08 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB for the third quarter of 2024. It contains comprehensive financial statements, management commentary, pipeline updates, and notes to the financial statements. It is clearly a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2024
2024-11-05 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report Jul 1-Sep 30, 2024' and contains comprehensive financial statements, including a summary of the period, CEO comments, pipeline information, and detailed financial breakdowns (operating income, expenses, etc.) for the group. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2024
2024-11-05 English
Vicore announces the Nomination Committee for the 2025 Annual General Meeting
Regulatory Filings Classification · 95% confidence The document is a press release announcing the appointment of a Nomination Committee for the upcoming 2025 Annual General Meeting. It describes the committee members and their responsibilities regarding board elections and remuneration proposals. Since it does not contain the actual AGM materials or voting results, but rather serves as a regulatory announcement regarding the preparation for the meeting, it falls under the category of general regulatory filings or announcements that do not fit into more specific categories like AGM-R or DVA.
2024-11-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.